TUMER IMMUNOLOGY

How does cancer arise? II

- Q: What causes dysregulated cell growth & proliferation?
- Intrinsic factors Genetic mutations on Oncogenes & Tumor suppressor genes
- Environmental factors Radiation, and others Carcinogens
- Microbial infections Viruses (viral oncogenes)

 and Bacteria


The Strategies for Cancer Therapy

The best scenario - Kill all the tumor cells without destroy others in the body

- 1. Surgery remove tumor cells & tissues physically
- 2. Radiotherapy non-selective, strong side effect
- 3. Chemotherapy non-selective, strong side effect
- 4. Gene therapy relatively selective
- Targeted therapy relatively selective to cancer cells
- 6. Immunotherapy => manipulate an immune response against tumor cells but not normal cells
 - => quite selective

Induction of T cell responses to tumors


Cross-priming (cross-presentation) mediated by APCs, ex. DCs



Immune responses to tumors


- 1. Adaptive immune responses to tumors:
- a. CD8 CTLs are the key players on the killing effect of tumors.
- b. CD4 T helper cells => cytokines => CTLs
- c. Abs => activating complements or Ab-dep cell-med toxicity=> preventing oncogenic viruses
- 2. Innate immune responses to tumors:
- a. NK cells kill many types of tumor cells that have reduced class-I but express ligands for activating NK cells.
- b. Macrophages => Ab-med phagocytosis=> Cytokines (TNF-a)

Tumor vaccines-Targeting DCs



Passive Immunotherapy for tumors

Adoptive cellular therapy



Therapy with Anti-tumor Monoclonal Abs

Tumor-specific antibody




Tumor-specific antibody conjugated to toxin




Tumor-specific antibody conjugated to radioisotope




Antibodies bind to the tumor cell



Antibody-toxin conjugates bind to the tumor cell



Radioactive antibody binds to the tumor cell



NK cells with Fc receptors (CD16) are activated to kill the tumor cells

Conjugates are internalized, killing the cell

Radiation kills the tumor cell and neighboring tumor cells

Figure 14-17 Immunobiology, 6/e. (© Garland Science 2005)

Approved Anti-tumor mAb

Specificity of antibody	Form of antibody used	Clinical trials
Her-2/Neu	Humanized mouse monoclonal	Breast cancer (approved for clinical use)
CD20 (B cell marker)	Humanized mouse monoclonal	B cell lymphoma
CD10	Humanized mouse monoclonal, immunotoxin	B cell lymphoma; in routine use to purge bone marrow of residual tumor cells
CEA	Humanized mouse monoclonal	Gastrointestinal cancers, lung cancer
CA-125	Mouse monoclonal	Ovarian cancer
GD3 ganglioside	Humanized mouse monoclonal	Melanoma

Abbreviation: CEA, carcinoembryonic antigen.